

Subscription rates	1 year	2 years
Individual rate <sup>(1)</sup>	€130 (174 USD)	€240 (322 USD)
Student rate <sup>(1)</sup>	€60 (80 USD)	€112 (150 USD)
Institutional rate <sup>(1)(2)</sup>	€325 (436 USD)	€630 (844 USD)

1- For Solidarity subscription rates see the preceding page.

2- Commercial companies and institutions.

- ☐ **Yes, I would like to subscribe to Prescire International**
- ☐ **Please send me a free sample issue of the French journal Prescire**

Title: ☐ Mr ☐ Ms

Last Name: .....

First Name: .....

Address (1): .....

.....

Zip: ..... City: .....

Country: .....

Tel: .....

Fax: .....

E-Mail (must be provided): .....

.....

Occupation: .....

working in the community, hospital, university, industry,  
other (please circle)

1- Give the format of the address as it is used in your country.

☐ I enclose a cheque for € .....  
or USD .....

☐ I pay € .....  
or USD .....  
by Credit card

☐ VISA

☐ EUROCARD/MASTERCARD

☐ AMERICAN EXPRESS

Card number: | | | | | | | | | | | | | | | | | |

Expiry date: | | / | |

Signature: .....

Postage and handling charges are included in the quoted prices. Subscribers outside the European Union who are subject to value added tax (VAT) may pay the ex-tax cost: divide the full cost by 1.021. EU subscribers subject to VAT must provide us with their VAT code number.

**Send your order with payment to:**

**Prescire International**

**83 bd Voltaire - 75558 PARIS CEDEX 11 - FRANCE**

**Fax: + 33 1 49237648**

**e-mail: international@prescire.org**

**website: www.english.prescire.org**



## Prescire's at-a-glance drug rating system

### Our ratings on a new drug's therapeutic advantage

Since its creation 30 years ago, *Prescire* has used a rating system to provide an at-a-glance estimate of the therapeutic progress (or lack thereof) of the new drugs and indications analysed each month. A pictogram represents *Prescire's* mascot, nicknamed Gaspard. Gaspard's different facial expressions and body positions correspond to seven pre-defined ratings. *Prescire's* at-a-glance rating system for new drugs and new indications is explained on the last page of the "New Products" section (this issue p 68). It also forms the basis for the yearly Drug Awards (Pilule d'Or) ceremony in January (this issue pages 79-82 and online at [www.english.prescire.org](http://www.english.prescire.org)). For example, "Nothing new" indicates that the product has no proven advantages over other drugs belonging to the same, plethoric pharmacological class. Many such products are simple me-toos.

### What matters is therapeutic progress

Drug regulatory agencies do not require manufacturers to prove that their new products represent a therapeutic advance before granting marketing authorisation. Yet therapeutic progress is precisely what matters to patients, and this is why *Prescire* examines each new drug's place compared with existing options.

*Prescire's* standardised method for assessing pharmaceuticals is a multistep process: we first examine the condition or clinical setting for which the drug is proposed; then the natural course of the disease, the efficacy and safety of existing treatments, and the most relevant outcome measures. This is followed by a systematic search for clinical data on the efficacy and adverse effects of the new drug, and an assessment of the level of evidence.

### Gaspard sums up Prescire's review of the evidence

Based on our independent analysis of clinical data, we form a judgement as to whether or not the new drug is beneficial for patients or whether or not its harmful effects outweigh the benefit. Gaspard's demeanor informs our readers, at a glance, of the conclusion of our assessment based on extensive, painstaking work by a large multidisciplinary team. This allows patients and healthcare professionals to distinguish useful new products from those that are simply useless or, worse, downright dangerous, based on hard endpoints.

*Prescire's* conclusions, represented in these ratings, are often in line with those of other independent teams worldwide.

©Prescire